<DOC>
	<DOCNO>NCT00897923</DOCNO>
	<brief_summary>RATIONALE : Measuring number radiolabeled white blood cell non-Hodgkin 's lymphoma tumor may help doctor predict well patient respond treatment , may help study cancer future . PURPOSE : This study measure radiolabeled white blood cell patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Imaging Radiolabeled White Blood Cells Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine number indium In 111-labeled peripheral blood mononuclear cell ( PBMCs ) indium In 111-labeled polymorphonuclear leukocyte ( PMNLs ) traffic lymphoma tumor prior therapy patient non-Hodgkin 's lymphoma . - Compare number PBMC PMNL traffic prior vs therapy patient . - Compare , preliminarily , number vivo baseline ( i.e. , pre-therapy ) traffic PBMCs v PMNLs patient . - Gather important data regard inter- intra-patient variability effector cell traffic tumor . - Assess relationship response 8-12 week magnitude baseline effector cell traffic magnitude post-rituximab effector cell traffic patient . OUTLINE : This multicenter study . Patients assign 1 2 group . - Group I : Patients receive autologous indium In 111 ( ^111In ) -labeled peripheral blood mononuclear cell day 0 . - Group II : Patients receive autologous ^111In-labeled polymorphonuclear leukocyte day 0 . In group , patient undergo blood collection day 0 . Patients undergo full-body single-photon emission-computed tomography ( SPECT ) scan 4 hour cell infusion day 2 . The label imaging process may repeat least 1 course anticancer treatment . Cellular uptake measure reader/visual interpretation , semiquantitative grading system , tumor-to-background uptake ratio . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonHodgkin 's lymphoma Indolent aggressive disease Planning receive new regimen start regimen cancer therapy At least one tumor lesion measurable two dimension ≥ 1.5 cm CT scan PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy ≥ 3 month No concurrent medical complication would preclude study compliance Not pregnant nursing PRIOR CONCURRENT THERAPY : At least 3 week since prior chemotherapy ( except nonmyelosuppressive treatment ) At least 3 week since prior radiation therapy Concurrent rituximab allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>